Carregant...
Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice
Sorafenib may improve progression-free survival (PFS) and overall survival (OS) of advanced hepatocellular carcinoma (HCC). However, the survival benefit is short lived and survivals after progressive disease (PD) have not been well characterized. This study aimed to evaluate the survival predictors...
Guardat en:
| Publicat a: | Medicine (Baltimore) |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wolters Kluwer Health
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4554055/ https://ncbi.nlm.nih.gov/pubmed/25860213 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000000688 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|